本研究旨在评估卵巢恶性肿瘤风险算法 (ROMA)、哥本哈根指数 (CPH-I) 和卵巢附件报告和数据系统 (O-RADS) 对卵巢癌 (OC) 术前预测的诊断性能。对2020年5月至2022年12月在顺化医药大学医院、顺化中心医院妇产科收治的462名卵巢肿瘤患者进行了前瞻性队列研究。使用癌症计算ROMA和CPH-I抗原 125 (CA125)、人附睾蛋白 4 (HE4) 水平以及患者特征（年龄和绝经状态）。 O-RADS 标准用于描述超声检查结果中的卵巢肿瘤特征。与组织病理学结果比较，计算ROMA、CPH-I和O-RADS单独或联合CA125/HE4对OC的预测值。 462例患者中，良性肿瘤381例，交界性肿瘤11例，OC 50例。在最佳截止点，ROMA 和 CPH-I 曲线下面积 (AUC) 分别为 0.880（95% 置信区间 [CI]=0.846-0.909）和 0.890（95% CI=0.857-0.918），ROMA CPH-I 的敏感性/特异性 (Se/Sp) 分别为 68.85%/95.01% 和 77.05%/91.08%。 O-RADS ≥3 的 AUC 为 0.949 (95% CI=0.924-0.968)，Se/Sp 为 88.52%/88.98% (p<0.001)。 O-RADS 与 CA125 组合显示出最高的预测价值，AUC 为 0.969 (95% CI=0.949-0.983)，Se/Sp 为 98.36%/86.09% (p<0.001)。ROMA、CPH-I、O- RADS、O-RADS CA125 和 O-RADS HE4 模型对 OC 表现出良好的预测价值； O-RADS 和 CA125 的组合产生了最高值。© 2025。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

This study aimed to assess the diagnostic performance of the Risk of Ovarian Malignancy Algorithm (ROMA), Copenhagen Index (CPH-I), and Ovarian Adnexal Reporting and Data System (O-RADS) for the preoperative prediction of ovarian cancer (OC).A prospective cohort study was conducted on 462 patients diagnosed with ovarian tumors admitted to the Departments of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy Hospital, and Hue Central Hospital from May 2020 to December 2022. ROMA and CPH-I were calculated using cancer antigen 125 (CA125), human epididymal protein 4 (HE4) levels, and patient characteristics (age and menopausal status). O-RADS criteria were applied to describe ovarian tumor characteristics from ultrasound findings. Compared with histopathological results, the predictive values of ROMA, CPH-I, and O-RADS alone or in combination with CA125/HE4 for OC were calculated.Among 462 patients, 381 had benign tumors, 11 had borderline tumors, and 50 had OC. At optimal cut-off points, ROMA's and CPH-I's areas under the curves (AUCs) were 0.880 (95% confidence interval [CI]=0.846-0.909) and 0.890 (95% CI=0.857-0.918), respectively, and ROMA and CPH-I sensitivities/specificities (Se/Sp) were 68.85%/95.01% and 77.05%/91.08%, respectively. O-RADS ≥3 yielded an AUCs of 0.949 (95% CI=0.924-0.968), with Se/Sp of 88.52%/88.98% (p<0.001). Combining O-RADS with CA125 demonstrated the highest predictive value, with AUCs of 0.969 (95% CI=0.949-0.983) and Se/Sp of 98.36%/86.09% (p<0.001).The ROMA, CPH-I, O-RADS, O-RADS + CA125, and O-RADS + HE4 models demonstrated good predictive values for OC; the combination of O-RADS and CA125 yielded the highest values.© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.